Hikma Pharmaceuticals (LON:HIK) Reaches New 12-Month Low – What’s Next?

Hikma Pharmaceuticals PLC (LON:HIK) shares hit a new 52-week low during mid-day trading on Thursday . The company traded as low as GBX 1,520 and last traded at GBX 1,531, with a volume of 305632 shares. The stock had previously closed at GBX 1,530.

Analysts Set New Price Targets

Several brokerages recently commented on HIK. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,360 target price on shares of Hikma Pharmaceuticals in a report on Friday, November 7th. Peel Hunt reaffirmed a “buy” rating and issued a GBX 2,170 price objective on shares of Hikma Pharmaceuticals in a research note on Friday, November 7th. JPMorgan Chase & Co. decreased their price objective on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a research report on Friday, November 7th. Finally, Berenberg Bank lowered their target price on shares of Hikma Pharmaceuticals from GBX 2,510 to GBX 2,300 and set a “buy” rating for the company in a research note on Thursday, November 6th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of GBX 2,416.

Hikma Pharmaceuticals Trading Down 0.1%

The firm’s 50-day moving average price is GBX 1,687.84 and its 200 day moving average price is GBX 1,825.33. The company has a market cap of £3.38 billion, a price-to-earnings ratio of 9.15, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82.

Insiders Place Their Bets

In related news, insider Victoria Hull purchased 3,214 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was purchased at an average cost of GBX 1,547 per share, with a total value of £49,720.58. Also, insider Mazen Darwazah bought 315,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was purchased at an average cost of GBX 1,601 per share, with a total value of £5,043,150. Over the last ninety days, insiders purchased 462,214 shares of company stock worth $734,939,058. 18.15% of the stock is currently owned by company insiders.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.